Cognitive effects of nicotinic cholinergic receptor agonists in nonhuman primates

Drug Development Research

Volumn 38, Issue 3-4, 1996, Pages 196-203

  Buccafusco, J J ^a,b   Prendergast, M A ^a   Terry Jr , A V ^a,c   Jackson, W J ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Cognitive effects; Nicotine

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; ISOARECAIDINE METHYL ESTER; NERVE GROWTH FACTOR RECEPTOR; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; TACRINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL STRAIN; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VITRO STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA; MALE; NONHUMAN; RECEPTOR DENSITY; RECEPTOR UPREGULATION; TASK PERFORMANCE;

EID: 0030457675     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199607/08)38:3/4<196::AID-DDR8>3.0.CO;2-H     Document Type: Article

References (23)

1. 3H]acetylcholine nicotinic recognition sites in human brain: Characterization of agonist binding. Neurosci Lett 83:298-302.
2. Arneric SP, Williams M (1994): Nicotinic agonists in Alzheimer's disease: Does the molecular diversity of nicotine receptors offer the opportunity for developing CNS-selective cholinergic channel activators? In Racagni G, Brunello N, Langer SZ (eds): International Academy of Biomedical Drug Research, Vol 7: Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. Basel: Karger, pp 58-70.
3. Arneric SP, Anderson EJ, Bannon AW, Briggs CA, Buccafusco JJ, Brioni J, Cannon JB, Decker MW, Donnelly-Roberts D, Gopalakrishnan M, Holladay MW, Kyncl J, Marsh KG, Pauly J, Radek RJ, Rodrigues AD, Sullivan JP (1995a): Preclinical pharmacology of ABT-418: A prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drug Rev 1:1-26.
4. Arneric SP, Sullivan JP, Williams M (1995b): Neuronal nicotinic acetylcholine receptors. Novel targets for central nervous system therapeutics. In Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press Ltd, pp 95-110.
5. Barclay KL, Kheyfets S (1989): Alzheimer's Disease and Related Disorders, New York: Alan R. Liss.
6. Bartus RT, Dean RL, Pontecorvo MJ, Flicker C (1985): The cholinergic hypothesis: A historical overview, current perspective, and future directions. Ann NY Acad Sci 444:332-358.
7. Bjugstad KB, Mahnir VM, Kem WR, Arendash GW (1995): Longterm administration of the nicotinic receptor agonist GTS-21 improves water maze learning in aged rats without affecting the density of nicotinic receptor subtypes in neocortex and hippocampus. Soc Neurosci Abstr 21:159.
8. Brenner DE, Kukull WA, van Belle G, Bowen JD, McCormick WC, Teri L, Larson EB (1993): Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study. Neurology 43:293-300.
9. Buccafusco JJ, Jackson WJ (1991): Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in the young and aged monkey. Neurobiol Aging 12:233-238.
10. Buccafusco JJ, Jackson WJ, Gattu M, Terry Jr AV (1995a): Isoarecolone-induced enhancement of delayed matching-to sample performance in monkeys: Role of nicotinic receptors. Neuroreport 6:1223-1227.
11. Buccafusco JJ, Jackson WJ, Terry Jr AV, Marsh KC, Decker MW, Arneric SP (1995b): Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: A novel cholinergic channel activator for memory enhancement. Psychopharmacology 120:256-266.
12. Butcher LL, Wolf NJ (1986): Central cholinergic systems: Synopsis of anatomy and overview of physiology and pathology. In Scheibel AB, Wechsler AF (eds); Substrates of Alzheimer's Disease. New York: Academic Press, pp 73-86.
13. Elrod K, Buccafusco JJ, Jackson WJ (1988): Nicotine enhances delayed matching-to-sample performance by primates. Life Sci 43:277.
14. Jackson WJ, Elrod K, Buccafusco JJ (1989): Delayed matching-to-sample in monkeys as a model for learning and memory deficits: Role of brain nicotinic receptors. In Edwin MM, Simpkins JW, Yamamoto J (eds): Novel Approaches to the Treatment of Alzheimer's Disease. New York: Plenum Publishing Corporation, pp 39-52.
15. Levin ED (1992): Nicotinic systems in cognitive function. Psychopharmacology 108:417-431.
16. Levin ED, Lee C, Rose JE, Reyes A, Ellison G, Jaravik M, Gritz E (1990): Chronic nicotine and withdrawal effects on radial-arm performance in rats. Behav Neural Biol 53:269-276.
17. Lippiello PM, Gray JA, Peters S, Grigoryan G, Hodges H, Summers K, Giacobini E, Collins AC (1995): Metanicotine: A nicotinic agonist with CNS selectivity - In vivo characterization. Soc Neurosci Abstr 21:605.
18. Perry EK, Perry RH (1983): Acetylcholinesterase in Alzheimer's disease. In Reisberg B (ed): Alzheimer's Disease The Standard Reference. London: Collier Macmillan, pp 93-99.
19. Reavill C, Spivak CE, Stolerman IP, Waters JA (1987): Isoarecolone can inhibit binding and produce nicotine-like discriminative stimulus effects in rats. Neuropharmacology 26:789-792.
20. Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989): The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer's type. Br J Psychiatr 154:797-800.
21. Terry AV, Buccafusco JJ, Jackson WJ (1993): Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance by monkeys. Pharmacol Biochem Behav 45:925-929.
22. Terry AV, Clarke MSF (1994): Nicotine stimulation of nerve growth factor receptor expression. Life Sci 55:PL91-PL98.
23. Waters JA, Spivak CE, Hermsmeier M, Yadav JS, Liang RF, Gund TM (1988): Synthesis, pharmacology and molecular modeling studies of semi-rigid nicotinic agonists. J Med Chem 31: 545-554.